Fresh from the pipeline: Bortezomib.
A Paramore, S Frantz - Nature reviews Drug discovery, 2003 - search.ebscohost.com
A Paramore, S Frantz
Nature reviews Drug discovery, 2003•search.ebscohost.comAbstract On 13 May 2003, Bortezomib (Velcade; Millenium) became the first proteasome
inhibitor to be approved by the US FDA. Bortezomib was approved for multiple myeloma, a
blood cancer that affects two to three people per 100,000, in record time-four months-on the
basis of positive outcomes in early-phase trials.
inhibitor to be approved by the US FDA. Bortezomib was approved for multiple myeloma, a
blood cancer that affects two to three people per 100,000, in record time-four months-on the
basis of positive outcomes in early-phase trials.
Abstract On 13 May 2003, Bortezomib (Velcade; Millenium) became the first proteasome inhibitor to be approved by the US FDA. Bortezomib was approved for multiple myeloma, a blood cancer that affects two to three people per 100,000, in record time-four months-on the basis of positive outcomes in early-phase trials.
search.ebscohost.com